Lyell Immunopharma Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 251
- Market Cap
- $373.7M
- Website
- http://www.lyell.com
Lyell's IMPT-314 CAR T-cell Therapy Shows Promise in B-Cell Lymphoma Trial
Lyell's IMPT-314 demonstrated a 94% objective response rate and a 71% complete response rate in CAR T-naive patients with large B-cell lymphoma.